Association Between cd163 Gene Polymorphisms and Sepsis Among Chinese Han Population

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by Chinese PLA General Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Chinese PLA General Hospital
ClinicalTrials.gov Identifier:
NCT01504243
First received: January 4, 2012
Last updated: NA
Last verified: December 2011
History: No changes posted
  Purpose

CD163 is a member of the scavenger receptor cysteine-rich family (SRCR) is exclusively expressed on cells of the monocyte lineage.CD163 acts to amplify inflammation and serves as a critical mediator of inflammatory response in the context of sepsis. This study was designed to investigate whether CD163 genomic variations were associated with the prognosis of sepsis. We sequenced 30 sepsis patients with CD163 gene of seventeen exons by PCR sequencing. When analyzing the results of sequencing, we found five gene polymorphisms located in exon-2,exon-5 and exon-11, respectively. Compare with the NCBI dbSNP and Hapmap database, one polymorphisms located in exon-2 is non-synonymous variation rs3210140, two polymorphisms located in exon-5 are synonymous variations rs4883264 and rs4883263, the last two located in exon-11 are synonymous variations rs61729512 and rs150018775 . Five common polymorphisms (rs2234237,rs2234246) within the CD163 gene were detected in 200 patients with severe sepsis and in 200 healthy control subjects. This study was explored that whether or not polymorphisms detected within the CD163 gene may play a major role in the predisposition to prognosis of sepsis in a Chinese Han cohort.


Condition
Sepsis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Association Between cd163 Gene Polymorphisms and Sepsis Among Chinese Han Population

Resource links provided by NLM:


Further study details as provided by Chinese PLA General Hospital:

Estimated Enrollment: 400
Study Start Date: May 2010
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Control
normal person under medical examination
sepsis
SIRS plus inflammation

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

All subjects were selected from among inpatients who were hospitalized between September 2009 and October 2011 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's Liberation Army (CPLA) General Hospital.

Criteria

Inclusion Criteria:

  • Sepsis met the criteria recommended by 1991 ACCP/SCCM Joint Meeting and by the diagnostic criteria developed at the 2001 International Sepsis Definition Conference.

Exclusion Criteria:

  • (1) younger than 18 years of age; (2) acquired immunodeficiency syndrome; (3) reduced polymorphonuclear granulocyte counts (< 500 μL-1); (4) died within 24h after admission into the ICU, or refused to participate in the study, or declined treatment during the period of observation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01504243

Contacts
Contact: Zhao xv Jiang, Ms +86 15010540218 shanyuan1101@sina.com

Locations
China, Beijing
Chinese PLA General Hospital Recruiting
Beijing, Beijing, China
Sponsors and Collaborators
Chinese PLA General Hospital
Investigators
Study Director: Li xin Xie, MD Respiratory Disease Department of chinese PLA General Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01504243     History of Changes
Other Study ID Numbers: 20111013-009(1), 2009BAI86B03
Study First Received: January 4, 2012
Last Updated: January 4, 2012
Health Authority: China: Ethics Committee

Keywords provided by Chinese PLA General Hospital:
CD163;
SNPs;
prognosis;
control(normal person)

Additional relevant MeSH terms:
Sepsis
Toxemia
Infection
Inflammation
Pathologic Processes
Systemic Inflammatory Response Syndrome

ClinicalTrials.gov processed this record on October 22, 2014